OncoMatch/Clinical Trials/NCT05370430
BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
Is NCT05370430 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies BAFFR-CAR T cells for relapsed or refractory b-cell non-hodgkin's lymphoma.
Treatment: BAFFR-CAR T cells — A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: TNFRSF13C overexpression
BAFF-R expression on lymphoma cells required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: allogeneic stem cell transplant
Prior allogeneic SCT
Cannot have received: autologous stem cell transplant
Exception: allowed if ≥ 6 months before leukapheresis
Autologous SCT < 6 months before leukapheresis
Lab requirements
Blood counts
anc ≥ 1000/μl, platelets ≥ 75,000/μl (exceptions for bm involvement)
Kidney function
crcl ≥ 50 ml/min
Liver function
bilirubin ≤ 1.5x uln (except gilbert's), ast/alt < 3x uln
Cardiac function
lvef ≥ 45%, qtcf ≤ 480 ms, o₂ saturation > 91% on room air
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
- Stanford University · Stanford, California
- University of Kansas Hospital · Kansas City, Kansas
- University of Minnesota · Minneapolis, Minnesota
- Atrium Health Levine Cancer Institute - Morehead · Charlotte, North Carolina
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify